NCT00820508View on ClinicalTrials.gov

Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Hematological DiseaseLymphoid Malignancies
Interventions
DRUG

CHR-2845

Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days

Trial Locations (4)

2060

ZNA Stuivenberg, Antwerp

Unknown

Institut Paoli-Calmettes, Marseille

1007 MB

VU University Medical Center, Amsterdam

3015 CE

Erasmus University Medical Center, Rotterdam

Sponsors
All Listed Sponsors
lead

Chroma Therapeutics

INDUSTRY

NCT00820508 - Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies | Biotech Hunter | Biotech Hunter